Objective: To explore the association between statins and colorectal cancer and provide evidence for the prevention of colorectal cancer. Methods: Literatures about statins and colorectal cancer published from January 2000 to January 2020 were retrieved from CNKI, Wanfang data, PubMed and Cochrane Library database. The literatures which met the inclusion criteria were collected, and the Newcastle-Ottawa Scale and Jadad score were used to assess the studies. Meta-analysis was performed with statistical software Revman 5.0 and Stata 12.1. Results: A total of 31 studies, involving more than 1.62 million subjects, were included in the analysis. The case-control study (RR=0.93, 95%CI: 0.88-0.98), the cohort study (RR=0.75, 95%CI: 0.63-0.88) and the randomized controlled trial (RR=0.79, 95%CI: 0.65-0.97) showed moderate protective effect of statins. Using statin <5 years (RR=0.86, 95%CI: 0.76-0.96), average daily dosage ≥34 mg (RR=0.81, 95%CI: 0.66-0.98) and lipid-soluble statins (RR=0.86, 95%CI: 0.74-0.99) also had preventive effect on colorectal cancer; while lovastatin (RR=1.07, 95%CI: 1.00-1.14) increased the risk of colorectal cancer. Conclusion: Statins have protective effect on colorectal cancer.
目的： 探讨他汀类药物与结直肠癌间的关系，为结直肠癌的预防提供循证医学依据。 方法： 系统检索中国知网（CNKI）、万方数据知识服务平台（Wanfang data）、PubMed和Cochrane Library数据库中从2000年1月至2020年1月所有他汀类药物与结直肠癌研究的文献，按照纳入排除标准选择文献，并用纽卡斯尔-渥太华量表和Jadad评分进行评价。采用Revman 5.0和Stata 12.1软件进行Meta分析。 结果： 共纳入31篇文献，162万受试者参与。病例对照研究（RR=0.93，95%CI：0.88~0.98）、队列研究（RR=0.75，95%CI：0.63~0.88）和随机对照试验研究（RR=0.79，95%CI：0.65~0.97）均显示他汀类药物对结直肠癌具有一定保护作用；服用他汀类药物<5年（RR=0.86，95%CI：0.76~0.96）、日均服用剂量≥34 mg（RR=0.81，95%CI：0.66~0.98）和服用脂溶性他汀类药物（RR=0.86，95%CI：0.74~0.99）会降低结直肠癌发生风险。 结论： 他汀类药物对结直肠癌有一定的预防作用。.